REGISTER
Nominations Announced for Enterprise Categories of the Inaugural Huashan Awards

Following quantitative evaluation and expert voting, the nomination list for the enterprise categories of the Inaugural Huashan Awards has been officially announced. A total of 18 companies have been nominated across three enterprise award categories.

Initiated by MedJ and Tonacea, the Huashan Awards aim to identify value-based benchmarks in China’s innovative drug ecosystem through objective indicators, independent expert review, and international evaluation standards. The enterprise awards focus on recognizing leading, fast-growing, and high-potential innovators shaping China’s pharmaceutical and biotechnology landscape.

Based on predefined quantitative metrics, relevant data were extracted from authoritative databases and analyzed to generate the longlist. The results were then submitted to the Huashan Awards Enterprise Review Committee for voting. Each category produced six nominated companies.

The Enterprise Review Committee consists of 11 experts with deep experience in innovative drug R&D, corporate leadership, and industry investment, including founders and chairpersons of leading Chinese pharmaceutical companies, former China heads of multinational pharmaceutical firms, and managing directors or founders of top investment institutions. The committee brings both industry depth and international perspective to the evaluation process.

The Huashan Awards include three enterprise categories: Best Innovative Big Pharma, Best Innovative Growing Biopharma, and Best Innovative Rising Biotech. The nomination results are as follows.

Final award recipients will be announced on January 17 at the Huashan Awards Ceremony and the 2026 China Innovative Drug New Year Outlook Conference.

Best Innovative Big Pharma

This award recognizes large pharmaceutical companies or China-based subsidiaries of multinational companies with strong comprehensive capabilities, sustained innovation capacity, significant market influence, and stable commercialization performance.

Nominated Companies:

  1. BeOne Medicines

  2. Eli Lilly and Company (China)

  3. Hengrui Pharmaceuticals

  4. AstraZeneca (China)

  5. Merck Sharp & Dohme (MSD) (China)

  6. Novartis (China)

Included in the Longlist but Not Nominated:

  1. Bristol Myers Squibb (BMS) (China)

  2. Roche (China)

  3. Pfizer (China)

  4. Hansoh Pharmaceutical (China)

  5. GlaxoSmithKline (GSK) (China)

  6. Amgen (China)

*Nominated companies are not repeated.

Best Innovative Growing Biopharma

This award recognizes Chinese innovative pharmaceutical companies with strong growth momentum, robust R&D investment, and rapidly advancing pipelines, typically with annual revenues between RMB 1 billion and RMB 10 billion.

Nominated Companies:

  1. Innovent Biologics

  2. Akeso

  3. Allist Pharmaceuticals

  4. Legend Biotech (China)

  5. 3SBio

  6. RemeGen

Included in the Longlist but Not Nominated:

  • Junshi Biosciences

  • Zai Lab

  • Henlius Biotech

  • InnoCare Pharma

  • China Medical Systems (CMS)

  • Simcere Pharmaceutical Group

*Nominated companies are not repeated.

Best Innovative Rising Biotech

This award focuses on early-stage biotech companies with disruptive technology platforms, proprietary intellectual property, and strong First-in-Class (FIC) or Best-in-Class (BIC) development potential.

Nominated Companies:

  1. Kelun-Biotech

  2. Biokin Pharmaceutical

  3. Zelgen Biopharmaceuticals

  4. Harbour BioMed

  5. Keymed Bio

  6. Duality Biotherapeutics

Included in the Longlist but Not Nominated:

  • Alphamab Oncology

  • CStone Pharmaceuticals

  • Genrix Bio

  • Mabwell

  • Lepu Biopharma

  • ImmuneOnco

*Nominated companies are not repeated.

0
0
Loading